{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:56:58Z","timestamp":1771037818303,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CorEvitas LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40744-024-00700-2","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T08:01:37Z","timestamp":1722067297000},"page":"1237-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct05572567","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4003-8842","authenticated-orcid":false,"given":"Koshiro","family":"Sonomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4228-2056","authenticated-orcid":false,"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Onofrei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4998-5747","authenticated-orcid":false,"given":"Jacqueline","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-0511","authenticated-orcid":false,"given":"Zachary","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekta","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-0665","authenticated-orcid":false,"given":"Naonobu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8453-6731","authenticated-orcid":false,"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/14397595.2013.854059","volume":"24","author":"H Yamanaka","year":"2014","unstructured":"Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24:33\u201340.","journal-title":"Mod Rheumatol"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41232-020-00133-8","volume":"40","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. Rheumatoid arthritis. Inflamm Regen. 2020;40:20.","journal-title":"Inflamm Regen"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis. 2020;23:1676\u201384.","journal-title":"Int J Rheum Dis"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol. 2020;30:1\u20136.","journal-title":"Mod Rheumatol"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/ijr.15.24","volume":"10","author":"T Koike","year":"2015","unstructured":"Koike T, Inui K. How can the treatment of rheumatoid arthritis be improved in Japan? Int J Clin Rheumatol. 2015;10:235\u201344.","journal-title":"Int J Clin Rheumatol"},{"issue":"Suppl 10","key":"700_CR6","first-page":"0829","volume":"72","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Kishimoto M, Nakano K, et al. International comparison of Japanese and US cross country utilization of RA medications [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10):0829.","journal-title":"Arthritis Rheumatol"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24:61.","journal-title":"Arthritis Res Ther"},{"key":"700_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four\u2013month phase\u00a0III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.","journal-title":"Arthritis Res Ther"},{"key":"700_CR10","unstructured":"Pfizer Inc. XELJANZ\u00ae (tofacitinib citrate) approved in Japan for the treatment of adults with rheumatoid arthritis (RA). 2013. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xeljanz_tofacitinib_citrate_approved_in_japan_for_the_treatment_of_adults_with_rheumatoid_arthritis_ra. Accessed Mar 1, 2023."},{"key":"700_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78:1048\u201354.","journal-title":"Ann Rheum Dis"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"700_CR13","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib): highlights of prescribing information. 2022. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed Feb 26, 2024."},{"key":"700_CR14","unstructured":"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed Mar 28, 2022."},{"key":"700_CR15","first-page":"201","volume":"10","author":"CA Salinas","year":"2023","unstructured":"Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023;10:201\u201323.","journal-title":"Rheumatol Ther"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/acr.22606","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Yang S, Chen L, et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67:1345\u201353.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 10","key":"700_CR17","first-page":"0802","volume":"72","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Yamanaka H, Harrold L, et al. Real-world DMARD experience and outcomes for rheumatoid arthritis patients in Japan: effectiveness [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10):0802.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"700_CR18","first-page":"0803","volume":"72","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Tanaka Y, Harrold L, et al. Real-world DMARD experience and outcomes for rheumatoid arthritis patients in Japan: safety [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10):0803.","journal-title":"Arthritis Rheumatol"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"700_CR21","unstructured":"Pfizer Japan Inc. XELJANZ\u00ae package insert for Japan. 2021. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00061355.pdf. Accessed Mar 1, 2023."},{"key":"700_CR22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/rheumatology\/ket466","volume":"53","author":"K Sonomoto","year":"2014","unstructured":"Sonomoto K, Yamaoka K, Kubo S, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford). 2014;53:914\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"700_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022504","volume":"99","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Chen YM, Huang WN, et al. Herpes zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan. Medicine (Baltimore). 2020;99:e22504.","journal-title":"Medicine (Baltimore)"},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/1079990041689665","volume":"24","author":"L Malmgaard","year":"2004","unstructured":"Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res. 2004;24:439\u201354.","journal-title":"J Interferon Cytokine Res"},{"key":"700_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/mr\/road063","volume":"34","author":"M Kuwana","year":"2024","unstructured":"Kuwana M, Sugiyama N, Momohara S, et al. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: interim analysis of post-marketing surveillance. Mod Rheumatol. 2024;34:272\u201386.","journal-title":"Mod Rheumatol"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u201352.","journal-title":"J Rheumatol"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3899\/jrheum.130466","volume":"41","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15\u201323.","journal-title":"J Rheumatol"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70:2148\u201351.","journal-title":"Ann Rheum Dis"},{"key":"700_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","volume":"6","author":"GW Reed","year":"2019","unstructured":"Reed GW, Gerber RA, Shan Y, et al. Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019;6:573\u201386.","journal-title":"Rheumatol Ther"},{"key":"700_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927179","volume":"13","author":"CT de Castro","year":"2022","unstructured":"de Castro CT, de Queiroz MJ, Albuquerque FC, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: systematic review and meta-analysis. Front Pharmacol. 2022;13: 927179.","journal-title":"Front Pharmacol"},{"key":"700_CR31","unstructured":"GlaxoSmithKline. Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over. 2018. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over\/. Accessed Dec 10, 2018."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00700-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:07:30Z","timestamp":1727158050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00700-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00700-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshiya Tanaka has received speaker fees and\/or honoraria from AbbVie, Asahi Kasei, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Pfizer Inc, Taiho, and Taisho, and has received research grants from Asahi Kasei, Chugai, Eisai, Mitsubishi-Tanabe, and Taisho. Yoshiya Tanaka is an Editorial Board member of<i> Rheumatology and Therapy<\/i>. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mitsumasa Kishimoto has received consulting fees and\/or honoraria from AbbVie, Amgen, Asahi Kasei Pharma, Ayumi Pharma, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, Ono Pharma, Pfizer Inc, Tanabe-Mitsubishi, and UCB Pharma. Koshiro Sonomoto has received speaking fees from AbbVie, Astellas, Chugai, Eli Lilly Japan, Gilead Sciences, Janssen, and Taisho, and has received research funding from UCB Japan. Koichi Amano has received speaker fees and\/or honoraria from AbbVie GK, Chugai, Eisai, GlaxoSmithKline, and Pfizer Japan Inc, and has received research grants from Chugai Pharmaceutical Co. Ltd. Masayoshi Harigai has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Eisai Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd, has received speaker\u2019s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd, and is a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb Co., and Teijin Pharma Ltd. Masayoshi Harigai was an employee of Tokyo Women\u2019s Medical University School of Medicine at the time of this study and is now employed at Sanno Hospital and International University of Health and Welfare. Alina Onofrei is an employee of CorEvitas, LLC. Jacqueline O\u2019Brien is an employee of CorEvitas, LLC. Zachary Margolin is an employee of CorEvitas, LLC. Christine Barr is an employee of CorEvitas, LLC. Yasushi Mizuno is an employee and shareholder of Pfizer Inc. Ekta Agarwal is an employee and shareholder of Pfizer Inc. Naonobu Sugiyama is an employee and shareholder of Pfizer Inc. Hisashi Yamanaka has received speaker fees or consultant fees from AbbVie, Asahi Kasei, Ayumi, Bristol Myers Squibb, Chugai, CorEvitas LLC, Eli Lilly, Fuji Yakuhin, Mochida, Pfizer Inc, Sato Seiyaku, Tanabe-Mitsubishi, Teijin Pharma, and YL Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This structured, secondary study was conducted within the CorEvitas Registry in accordance with the International Council for Harmonisation Guidelines for Good Clinical Practice and Ethical Guidelines for Medical and Health Research Involving Human Subjects. All patients provided written informed consent for participation in the registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}